SHLX 36.88 Shell Midstream Partners L.P. $SHLX Hit a 52

New Post Public Reply Private Reply Replies (0) Message Board

Nov 13, 2014 at 1:48 PM

SHLX 36.88 Shell Midstream Partners L.P. $SHLX Hit a 52 week high of 37.23 Closing the day 09:44 at 36.88 +0.10 +0.27% With a day low of 36.90 and a total volume of 11,779.

SHLX Recent Posts: http://investorshangout.com/Shell-Midstream-P...HLX-90647/

SHLX Shell Midstream Partners L.P. Recent Headline News

Antero Midstream Partners IPO Looks Strong And Steady
Don Dion - at Seeking Alpha - Tue Nov 04, 12:54PM CST

SHLX: 36.12 (-0.66), AM: 28.77 (-0.23)

IPO Calendar: Market Activity Reignites With 11 IPOs
at Investor's Business Daily - Mon Nov 03, 2:07PM CST
At least 11 IPOs are scheduled to begin trading this week, looking to raise about $1.7 billion and signaling a pickup after three weeks of sluggishness. After five or fewer initial public offerings in each of the past three weeks, the IPO calendar...
IPO: 23.66 (-0.21), JAGX: (), AR: 53.43 (-2.08), SHLX: 36.12 (-0.66), FRPT: 18.85 (+0.55), UPLD: 11.00 (-0.02), INCR: 21.42 (+0.52), NVRO: 25.76 (+0.66), CHRS: 13.86 (-0.56), TBK: 12.72 (-0.02), SKYS: 8.60 (+8.60), YDLE: 13.15 (+0.01), JYNT: 6.59 (+0.09), AM: 28.77 (-0.23), HUBS: 36.95 (+1.54)

Antero Midstream Partners IPO Offers Investors Long-Term 20% Income Growth With Low Risk
MLPData - Seeking Alpha - Mon Nov 03, 11:57AM CST
As commodity markets continue to look for a floor, the Master Limited Partnership IPO window is open to issuers with high-quality assets, low commodity exposure, and a large inventory of seasoned drop down assets. Over the past three weeks, CONE...
DM: 34.98 (+0.68), AR: 53.43 (-2.08), SHLX: 36.12 (-0.66), CNNX: 31.06 (+0.56), AM: 28.77 (-0.23)

InsiderInsights.com Daily Round Up 10/31/14: TTS, UFI, OPK, AAMC
InsiderInsights - at Seeking Alpha - Sun Nov 02, 11:12PM CST

SHLX: 36.12 (-0.66), VFC: 71.00 (-0.49), BBY: 35.28 (+0.08), AAMC: 492.00 (-34.00), BTN: 4.16 (+0.06), LLY: 67.54 (+0.14), FET: 26.62 (-0.57), SIEN: 17.38 (-0.12), TTS: 8.36 (-0.13), UA: 68.96 (-0.19), SPW: 91.95 (-0.67), AHGP: 67.54 (-0.11), OPK: 8.35 (-0.02), CATY: 26.74 (-0.28), MSFT: 49.36 (+0.58), AAPL: 112.53 (+1.28), UFI: 27.11 (-0.52), SCHW: 28.67 (-0.11)

U.S. IPO Weekly Recap: Boots, Barrels And Busts
Renaissance Capital IPO Research - Seeking Alpha - Sun Nov 02, 4:14AM CST
Four IPOs raised $1.2 billion during the past week, the third week in a row with five or less. Year-to-date, the IPO market has seen 235 initial public offerings raise $75 billion. The week's energy, health care, finance and consumer IPOs saw...
MOLG: 8.29 (-0.11), SHLX: 36.12 (-0.66), DPLO: 21.98 (-0.04), BOOT: 19.15 (+0.29), FSAM: 14.07 (-0.02), ATRA: 22.60 (+0.05), SIEN: 17.38 (-0.12)

MLPs are still a winner for choosy investors, analysts say
Seeking Alpha - at Seeking Alpha - Fri Oct 31, 5:50PM CDT

AMLP: 18.37 (-0.03), MLPA: 16.63 (+0.01), SHLX: 36.12 (-0.66), MLPG: 39.12 (+0.11), MLPL: 66.42 (+0.21), YMLP: 15.83 (-0.18), MLPI: 43.56 (+0.06), ETE: 61.17 (-0.78), PAA: 53.08 (unch), MLPN: 34.25 (-0.04), EMLP: 27.59 (-0.21), PAGP: 27.63 (-0.22), MLPS: 10.21 (+0.02), ETP: 64.38 (-0.16), AMJ: 50.50 (-0.08), MLPX: 19.03 (-0.24), EQM: 88.38 (+0.29), MLPY: 17.26 (-0.24), MMP: 85.84 (+0.37), SXL: 49.49 (-0.26)

Commodities Today: The Battle Over Oil And Steel Stocks Jumping
Matthew Smith - at Seeking Alpha - Wed Oct 29, 12:01PM CDT

RDS.B: 71.73 (-0.71), CLR: 52.54 (-1.73), SHLX: 36.12 (-0.66), RDS.A: 68.50 (-0.39), BP: 40.63 (-0.55), AKS: 6.33 (+0.09), X: 35.26 (+0.48), APC: 89.59 (-1.83)

Shell Midstream Partners MLP Jumps In Debut
at Investor's Business Daily - Wed Oct 29, 11:32AM CDT
Shell Midstream Partners (SHLX) shares soared on its first day of trading on the New York Stock Exchange. The master limited partnership and spin-off from Royal Dutch Shell (RDSA) priced at 23 per share late Tuesday, topping its expected range of...
SHLX: 36.12 (-0.66)

Shell Midstream Partners (SHLX) Stock Pops in First Trading Day After IPO
at The Street - Wed Oct 29, 10:46AM CDT
Shares of Shell Midstream Partners (SHLX) surged in morning trading Wednesday, the company's first trading day after its IPO.
SHLX: 36.12 (-0.66), RDS.A: 68.50 (-0.39)

U.S. Pipeline Operator Shell Midstream Comes on Stream on the NYSE
at The Street - Wed Oct 29, 8:35AM CDT
Royal Dutch Shell remains the majority shareholder.
SHLX: 36.12 (-0.66), RDS.A: 68.50 (-0.39)

Shell Midstream Partners raises $920M in IPO
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 6:43AM CDT

RDS.B: 71.73 (-0.71), RDS.A: 68.50 (-0.39), SHLX: 36.12 (-0.66)

Shell Midstream Partners, L.P. Announces Pricing of Initial Public Offering
GlobeNewswire - Tue Oct 28, 4:28PM CDT
Shell Midstream Partners, L.P., a limited partnership formed by Royal Dutch Shell, announced the pricing of its initial public offering of 40,000,000 common units representing limited partner interests at $23.00 per common unit. The underwriters of the offering have a 30-day option to purchase up to an additional 6,000,000 common units from Shell Midstream Partners. The common units will begin trading on the New York Stock Exchange on October 29, 2014 under the ticker symbol "SHLX." The offering is expected to close on or about November 3, 2014, subject to customary closing conditions.
SHLX: 36.12 (-0.66)

Shell Midstream Partners Could Flow Well Into Its IPO
Don Dion - at Seeking Alpha - Tue Oct 28, 12:01PM CDT

SHLX: 36.12 (-0.66)

Shell Midstream looks to be largest MLP IPO in more than a decade
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 11:58AM CDT

RDS.B: 71.73 (-0.71), RDS.A: 68.50 (-0.39), SHLX: 36.12 (-0.66)

Week Ahead: 3 IPOs Planned For The Week Of October 27 Include Boots, Breast Implants And Pipelines
Renaissance Capital IPO Research - Seeking Alpha - Tue Oct 28, 9:29AM CDT
Just three deals are on the IPO calendar for the week of October 27, with total proceeds expected to reach $900 million. Last week saw 3 IPOs raise $163 million , while 4 postponed and 4 more withdrew. The S&P recently had the year's largest...
SHLX: 36.12 (-0.66), SIEN: 17.38 (-0.12)

Weekly Intelligence For MLP Investors
MLPData - at Seeking Alpha - Mon Oct 27, 6:44PM CDT
Buoyed by the Q3 announcements of strong distribution growth and pending record dates, investors continued to bid up MLP units this week as the quest for yield returned to the markets. The 2% yields seen just 10 days ago have now returned back to...
QEPM: 15.96 (+0.25), PSXP: 64.54 (-1.21), SHLX: 36.12 (-0.66), SUSP: 46.00 (+0.69), TLLP: 57.05 (-0.20)

Shell Midstream Partners Offers Investors 25% Total Return
MLPData - at Seeking Alpha - Sun Oct 26, 11:57PM CDT
Investors have been awaiting Shell's launch of their midstream master limited partnership, which is expected to price on October 28th. Shell Midstream Partners (Pending: SHLX ) is expected to price between $19-$21 with a target midpoint yield of...
PSXP: 64.54 (-1.21), RDS.B: 71.73 (-0.71), VLP: 45.92 (+1.40), SHLX: 36.12 (-0.66), RDS.A: 68.50 (-0.39), MPLX: 68.62 (+1.40)

What To Make Of The Shell Midstream Partners' IPO
Khurram Aziz - at Seeking Alpha - Fri Oct 24, 5:01PM CDT
Shell Midstream Partners' filing for an IPO on June 16, 2014, was big news to the oil world. Following the IPO, Shell Midstream will be an operating master limited partnership (MLP) carved out of Royal Dutch Shell for the purpose of owning,...
SHLX: 36.12 (-0.66)

Royal Dutch Shell Sets IPO Price Range for U.S. Pipeline Operator
at The Street - Tue Oct 21, 9:02AM CDT
The Anglo-Dutch group expects proceeds of at least $711 million from the sale of almost a third of Shell Midstream Partners.
SHLX: 36.12 (-0.66), RDS.A: 68.50 (-0.39), CELP: 19.64 (-0.93), PBFX: 24.90 (-0.09)

Shell Midstream sets IPO
at Investor's Business Daily - Mon Oct 20, 5:57PM CDT
Royal Dutch Shell (RDSA) announced the terms for its IPO of Shell Midstream Partners (SHLX). The new company plans to raise about $750 mil by offering 37.5 mil shares, with a 19-21 expected price range. The midpoint of 20 would give the new company a...
SHLX: 36.12 (-0.66)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

GORGIE Unleashes Berry Burst: Target's New Drink Star

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

PwC US and India Unite for Global Consultancy Powerhouse

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Surfing Dogs Ride Waves, Support Orphan Pets

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

First-Time Homeowners: Unseen Pitfalls of Insurance

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...